The Phase 3 announcement is a positive pipeline catalyst but the trial does not start until 2027, providing no near-term revenue or regulatory catalyst. Traders should watch for Health Canada approval milestones, enrollment updates, and potential partnership or financing announcements to fund the trial.
Price Chart
Executive Summary
Optimi Health announced plans for a Health Canada-authorized Phase 3 clinical trial evaluating MDMA-assisted therapy for PTSD, enrolling up to 100 veterans and frontline workers, expected to begin in 2027. The trial represents a significant pipeline catalyst for the company, advancing its synthetic MDMA toward potential registration, but remains early-stage with no revenue impact and substantial execution risk.
Key Facts
- Optimi announced plans for a Health Canada-authorized Phase 3 trial of MDMA-assisted therapy for PTSD.
- Trial expected to enroll up to 100 participants, focused on veterans and frontline workers.
- Trial expected to begin in 2027 — no near-term revenue or regulatory milestone.
- Primary endpoint is change in CAPS-5 score, the standard PTSD severity measure.
- None of Optimi's MDMA products have received market authorization from Health Canada.
- Clinics in Australia have been prescribing Optimi's MDMA since October 2024.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company with no reported revenue or trial costs in the filing.
Risk Factors
- Trial is not expected to begin until 2027 — long timeline with no near-term catalyst.
- No MDMA products have received market authorization from Health Canada; regulatory approval is uncertain.
- Pre-revenue company with no disclosed financials; trial costs and funding needs are unknown.
- Psychedelic therapy regulatory landscape remains uncertain in the US and Canada.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006065 |
| Document: f6k_091626.htm | 0001171843-26-006065 |
| Document: 0001171843-26-006065-index-headers.html | 0001171843-26-006065 |
| Document: 0001171843-26-006065-index.html | 0001171843-26-006065 |
| Document: 0001171843-26-006065.txt | 0001171843-26-006065 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $3.36 | awaiting T+5 | — | $3.25 (−3.27%) |
Oct 20, 2026 6d ago | 6-K | $3.36 | awaiting T+5 | — | $3.25 (−3.27%) |
Oct 7, 2026 19d ago | 6-K | $4.04 $3.17 | ▼ −21.66% | ▼ −20.68% | $3.25 (−19.55%) |
Oct 5, 2026 21d ago | SC 13G/A | $4.13 $3.50 | ▼ −15.25% | ▼ −15.12% | $3.25 (−21.31%) |
Sep 29, 2026 27d ago | 6-K | $4.78 $4.13 | ▼ −13.60% | ▼ −15.55% | $3.25 (−32.01%) |
Sep 23, 2026 4w ago | 6-K | $4.96 $4.71 | ▼ −5.04% | ▼ −4.37% | $3.25 (−34.48%) |
Sep 22, 2026 4w ago | 6-K | $4.96 $4.78 | ▼ −3.63% | ▼ −2.44% | $3.25 (−34.48%) |
Sep 16, 2026 5w ago | 6-K | $4.90 $4.96 | ▲ +1.22% | ▼ −0.60% | $3.25 (−33.67%) |
Sep 10, 2026 6w ago | 6-K | $4.50 $4.96 | ▲ +10.22% | ▲ +10.72% | $3.25 (−27.78%) |
Aug 26, 2026 8w ago | 6-K | $4.89 $4.70 | ▲ +3.89% | ▲ +4.15% | $3.25 (+33.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers